Abstract |
The aim of the study was to look for the association of FPGS 2752 G > A (rs1544105), FPGS 1994 A > G (rs10106), and GGH 452 C > T (rs 11545078), GGH -401C > T (rs 3758149) gene polymorphisms with methotrexate (MTX) treatment response and MTX-induced adverse events in South Indian Tamil patients with rheumatoid arthritis (RA). Further the influence of these gene polymorphisms on MTX polyglutamate levels was analyzed. A total of 330 patients with RA were investigated. FPGS gene polymorphisms were analyzed by TaqMan 5'nuclease assay and GGH gene polymorphisms were analyzed by PCR-RFLP. Methotrexate polyglutamates (nmol/L of packed erythrocytes) were measured by liquid chromatography mass spectrometry (LCMS/MS) method. We found that the heterozygous genotype of FPGS rs1544105 [p = 0.02, OR 1.93, 95% CI (1.15-3.35)] and FPGS rs10106 AG genotype [p = 0.01, OR 2.11, 95% CI (1.20-3.71)] were associated with MTX adverse events. FPGS rs1544105 and GGH -401C > T SNPs influenced the polyglutamate levels. None of the investigated SNPs seems to be associated with MTX treatment outcome.
|
Authors | Niveditha Muralidharan, Rajan Sundaram, Sunitha Kodidela, K G Chengappa, Christina Mary Mariaselvam, Durga P Misra, Vir S Negi |
Journal | The pharmacogenomics journal
(Pharmacogenomics J)
Vol. 20
Issue 2
Pg. 342-349
(04 2020)
ISSN: 1473-1150 [Electronic] United States |
PMID | 31611592
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antirheumatic Agents
- Peptide Synthases
- folylpolyglutamate synthetase
- Methotrexate
|
Topics |
- Adult
- Antirheumatic Agents
(adverse effects)
- Arthritis, Rheumatoid
(drug therapy, epidemiology, genetics)
- Female
- Gastrointestinal Diseases
(chemically induced, epidemiology)
- Humans
- India
(epidemiology)
- Male
- Methotrexate
(adverse effects)
- Middle Aged
- Peptide Synthases
(genetics)
- Polymorphism, Single Nucleotide
(genetics)
- Prospective Studies
|